Abstract
Background: Healthcare workers have frequently become infected with SARS-CoV-2 whilst treating patients with COVID-19. A variety of novel devices have been proposed to reduce COVID-19 cross contamination. Objective: To test whether a novel patient isolation hood was safe and comfortable, and could potentially reduce HCW COVID-19 infections. Methods: Prospective cohort study of 20 patients, entailing staff/patient questionnaires, and safety aspects of prototype isolation hoods. Prospective collection of HCW COVID-19 data. Assessment of isolation hood safety and practicality, and adverse event reporting. Outcome Measures: Questionnaires responses, adverse events reporting, rates of HCW infections during study period (20/6/2020 - 21/7/2020). HCW COVID-19 infections reported until last recorded HCW COVID-19 diagnosis (20/6/2020 - 27/9/2020). Results: Of the 60 (of 64) eligible individual staff surveys, 60 favoured isolation hood use. Staff were unanimous in: perceiving the hood as safe (60/60), preferring its use (56/56), and understanding its potential COVID-19 cross-contamination minimisation (60/60). All eight patients who completed the questionnaire thought the isolation hood helped prevent COVID-19 cross-infection, was safe, and comfortable. There were no reported patient safety adverse events. The overall attack COVID-19 attack rate from 20/6/2020-27/9/2020 among registered nurses was 3.4% (102/2994): ICUs 2.2% (3/138), Geriatric wards 13.2% (26/197), and COVID-19 Wards 18.3% (32/175). The COVID-19 attack rate among medical staff was: all junior medical staff 2.1% (24/932), senior medical staff 0.7% (4/607), aged care/rehabilitation 6.7% (2/30), and ICU all medical staff 8.6% (3/35). Conclusions: The isolation hood was strongly endorsed by staff and patients, and post-study became part of standard ICU therapy. ICU nurse COVID-19 infection rates were low. ICU HCWs feel safer when treating patients with COVID-19 using an isolation hood.
Competing Interest Statement
Conflicts Of Interest: A patent has been filed for the personal ventilation hood by the University of Melbourne/Western Health. The lead authors (Forbes McGain, Jason Monty) were the leads in this patent application. There are no other conflicts of interest. All other authors have no conflicts of interest.
Clinical Trial
Australian and New Zealand Clinical Trials Registry Number:ACTRN12620000500954p World Health Organization Universal Trial Number: U1111-1250-6657
Funding Statement
Funding: funding was obtained for this study from the Western Health Foundation and the University of Melbourne to pay for the construction of the first 17 isolation hoods.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
HREC Reference Number: HREC/63694/MH-2020 Melbourne Health Site Reference Number: 2020.129 Project Title: A personalised ventilation hood for Covid-19: A phase 1 study of a new device.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data shall be made available by the authors where appropriate data requests are made.
